WuXi Biologics has entered into a license and research service agreement with Vertex Pharmaceuticals for the development of an innovative trispecific T-cell engager (TCE) targeting B-cell mediated autoimmune diseases.
The agreement covers a preclinical-stage molecule and expands collaboration between the two companies in next-generation immunotherapy research.
Under the terms of the deal, Vertex has secured exclusive global rights to develop and commercialise the trispecific TCE. WuXi Biologics will receive an upfront payment and is eligible for additional development, regulatory and sales milestone payments, along with royalties on future sales. In parallel, WuXi Biologics will provide Vertex with contract research and development services to support the advancement of novel next-generation T-cell engagers.
The trispecific TCE was discovered using WuXi Biologics’ integrated discovery platforms and is designed to address autoimmune diseases driven by B-cell activity. The collaboration highlights WuXi Biologics’ CRDMO model, which integrates discovery, development and manufacturing capabilities to support global biopharmaceutical partners in advancing complex biologic modalities.
The agreement strengthens Vertex’s research pipeline in immune-mediated diseases while reinforcing WuXi Biologics’ position as a global provider of discovery and development solutions for advanced therapeutic platforms, including multispecific antibodies.
Also Read